Progressão da Esclerose Múltipla Remitente-Recorrente apesar da nova era de medicamentos

Autores

DOI:

https://doi.org/10.11606/issn.2176-7262.rmrp.2022.196823

Palavras-chave:

Esclerose múltipla, Progressão de doença, Terapias

Resumo

Objetivo. O presente estudo tem como objetivo avaliar as condições associadas à progressão de doença e disfunções dos pacientes com Esclerose Múltipla (EM). Métodos. Estudo observacional analítico longitudinal retrospectivo com 46 pacientes com EM de uma policlínica do Rio de Janeiro, Brasil. Foi utilizada a Escala de Incapacidade Funcional Expandida (EDSS) para classificar os pacientes de acordo com a incapacidade e estabelecer correlação com fatores de risco, tratamento e tempo de doença. Resultados. Dos 46 pacientes, 69,6% eram do sexo feminino e 67,4% eram brancos. Pacientes com menos sistemas funcionais afetados no início da EM levaram maior tempo para progressão da doença. Medicamentos de baixa eficácia foram associados a uma alta taxa de descontinuação do tratamento. Pacientes em tratamento contínuo levaram maior tempo para atingir valores mais altos de EDSS comparado com pacientes que descontinuaram o tratamento. Conclusão. Apesar do controle da EM com medicamentos de alta eficácia, os pacientes ainda apresentam alguma incapacidade. Os fatores que influenciaram a progressão da incapacidade foram: múltiplos sintomas no início da doença, mais de 30 anos no início da EM, atraso no diagnóstico e início do tratamento, entre outros.

Downloads

Não há dados estatísticos.

Biografia do Autor

Gutemberg Augusto Cruz dos Santos, Estacio de Sa University. Department of Neurology, Rio de Janeiro, (RJ), Brazil.

Neurologist, Medical Professor

Gabriel Etienne Brito de Salles, Estacio de Sa University. Rio de Janeiro, (RJ), Brazil.

Medical Student

Milenna Grisoli Martins da Silva, Estacio de Sa University. Rio de Janeiro, RJ, Brazil.

Medical Student

Roxanne Cabral Pinto Santos, Universidade Estácio de Sá

Medical Student

Referências

Ropper AH, Samuels M, Klein J, Prasad S. Adams and Victor's Principles of Neurology. Edition 11. New York: McGraw-Hill Education 2019.

Ribeiro TA, Duarte AL, Silva DJ, Borges FE, Costa VM, Papais-Alvarenga RM, et al. Prevalence of multiple sclerosis in Goiânia, Goiás, Brazil. Arq Neuropsiquiatr. 2019; May 77(5): 352-356. https://doi.org/10.1590/0004-282X20190032

Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clin Med (Lond). 2020; 20(4) 380-383. https://doi.org/10.7861/clinmed.2020-0292

Negreiros AA, Sousa-Munãz RL, Oliveira BE, Nóbrega PV, Monteiro LL. Clinical and epidemiological profile of patients diagnosed with multiple sclerosis in João Pessoa, Paraíba, Brazil. Arq Neuro-Psiquiatria. 2015; 73(9):741-745. https://doi.org/10.1590/0004-282X20150111

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444. https://doi.org/10.1212/WNL.33.11.1444

Damasceno A, Glehn FV, Brandão CO, Damasceno BP, Cendes F. Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci. 2013; 324(1-2):29-33. https://doi.org/10.1016/j.jns.2012.09.020

Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler J. 2020; 26(5):561-657. https://doi.org/10.1177/1352458519887328

Vasconcelos CC, Aurenção JC, Thuler LC, Camargo S, Alvarenga MP, Alvarenga RM. Prognostic factors associated with long-term disability and secondary progression in patients with Multiple Sclerosis. Multiple Sclerosis and Mult Scler Relat Disord. 2016; 8:27-34. https://doi.org/10.1016/j.msard.2016.03.011

Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, et al. Harrison's Principles of Internal Medicine. 19th edition. New York: McGraw Hill Education, 2015.

Alroughani R, Inshasi J, Deleu D., Al-Hashel J, Shakra M, Elalamy O. An overview of high-efficacy drugs for multiple sclerosis: Gulf region expert opinion. Neurol. Ther. 2019; 8(1):13–23. https://doi.org/10.6084/m9.figshare.7687670

Brazil. Department of Health. Ordinance nº 3, 2021, February, 5th, Official Diary of the Union, Edition: 31, section 1, p. 88.

Pour GA, Rasekhi AR. Multiple Sclerosis: a risk factor analysis in Iran. Arch Iran Med. 2002; 5(3):191-193.

Baggio BF, Teles RA, Renosto A, Alvarenga LF. Perfil epidemiológico de indivíduos com Esclerose Múltipla de uma associação de referência. Rev. Neurociênc. 2011; 19(3):458-61. https://doi.org/10.34024/rnc.2011.v19.8347

Teixeira CA. Clinical and epidemiological characteristics of 146 patients with multiple sclerosis followed up in the city of Fortaleza, CE, Brazil, between 1979 and 2010 [dissertation]. Fortaleza: Medical Course, Federal University of Ceara, 2011.

Martyn CN, Gale CR. The epidemiology of multiple sclerosis. Acta Neurol Scand Suppl. 1997; 169:3-7. https://doi.org/10.1111/j.1600-0404.1997.tb08143.x

Nazish S, Shahid R, Zafar A, Alshamrani F, Sulaiman AA, Alabdali M, et al. Clinical Presentations and Phenotypic Spectrum of Multiple Sclerosis at a University Hospital in Saudi Arabia. J Clin Neurol. 2018; 14(3):359–365. https://doi.org/10.3988/jcn.2018.14.3.359

Skoog B, Runmarker B, Windbland S, Ekholm S, Andersen O. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain. 2012; 135(3):900-11. https://doi.org/10.1093/brain/awr336

Ghezzi A, Pozzilli C, Liguori M, Marrosu MG, Milani N, Milanese C, et al. Prospective study of multiple sclerosis with early onset. Mult Scler. 2002; 8(2):115-118. https://doi.org/10.1191/1352458502ms786oa.

Debouverie M. Gender as a prognostic factor and it s impact on the incidence of multiple sclerosis in Lorraine, France. J Neurol Sci. 2009;. 286(1-2):14-17. https://doi.org/10.1016/j.jns.2009.07.012

Hawkins SA, McDonnell GV. Benign multiple sclerosis: Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999; 67(2):148-152. http://dx.doi.org/10.1136/jnnp.67.2.148

Hojjati SM, Hojjati AS, Baes M, Bijani A. Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran. Caspian J Intern Med. 2014; 5(1):5-8.

Décard BF, Wyl VV, Benkert P, Lorscheider J, Hänni P, Lienert C, et al. Time to relapse is comparable in pediatric- and adult-onset multiple sclerosis patients after the initiation of disease-modifying therapy. In: 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2018, October 10-12, Berlin, Germany.

Laffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-henriksen, et al. The optimal time to start treatment in relapsing remitting multiple sclerosis patients: results from the Big Multiple Sclerosis Data Network. In: 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2018, October 10-12, Berlin, Germany.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, et al. Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. Mult Scler J Exp Transl Clin . 2018; 4(4):1-10. https://doi.org/10.1177/2055217318814562

Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016; 9(1):5-48. https://doi.org/10.1016/j.msard.2016.07.003

Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo, Grand’Maison F, et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. Plos one. 2012; 7(6):e3866, 1-8. https://doi.org/10.1371/journal.pone.0038661

Tilbery CP, Fazzito MM, Jordy SS, Thomaz RB, Fernandes IR. Side effects of immunomodulatory drugs in the treatment of Multiple Sclerosis - experience in 118 cases. Rev. Neurociênc. 2009; 17(3):220-225.

Alves BC, Angeloni RV, Azalis LA, Pereira EC, Perazzo FF, Rosa PC, et al. Multiple sclerosis: a review of main treatments. Saúde Meio Ambient.. 2014; 3(2):19-34. https://doi.org/10.24302/sma.v3i2.542

Brazil, Ministerio da Saúde. Relatório de Recomendação: Protocolo Clínico e Diretrizes Terapêuticas Esclerose Múltipla. CONITEC, 2019; 20.

Nali LH; Moraes L, Fink MC, Callegaro D, Romano CM, Oliveira AC. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients. Arq. Neuro-Psiquiatr. 2014 Dec; 72(12):960-965. https://doi.org/10.1590/0004-282X20140142

Downloads

Publicado

2022-12-27

Como Citar

1.
Santos GAC dos, Salles GEB de, Silva MGM da, Cabral RC. Progressão da Esclerose Múltipla Remitente-Recorrente apesar da nova era de medicamentos. Medicina (Ribeirão Preto) [Internet]. 27 de dezembro de 2022 [citado 26 de fevereiro de 2024];55(4):e-196823. Disponível em: https://www.revistas.usp.br/rmrp/article/view/196823

Edição

Seção

Artigo Original
Bookmark and Share